Rho Capital Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Rho Capital Partners’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,766,666	Closed	-$57.4M	–	5
2022 Q1	$57.4M	Hold	3,766,666	–	–	39.74%	2
2021 Q4	$66.7M	Hold	3,766,666	–	–	43.3%	2
2021 Q3	$79.2M	Hold	3,766,666	–	–	44.14%	2
2021 Q2	$74.3M	Hold	3,766,666	–	–	6.8%	3
2021 Q1	$109M	Hold	3,766,666	–	–	10.53%	3
2020 Q4	$114M	Hold	3,766,666	–	–	60.06%	1
2020 Q3	$59.9M	Hold	3,766,666	–	–	49.9%	1
2020 Q2	$74.4M	Hold	3,766,666	–	–	48.16%	1
2020 Q1	$46.4M	Hold	3,766,666	–	–	46.79%	1
2019 Q4	$69.6M	Sell	3,766,666 -1	-0%	-$15	52.94%	1
2019 Q3	$52.2M	Hold	3,766,667	–	–	43.68%	2
2019 Q2	$55.1M	Buy	+3,766,667	New	+$55.1M	38.25%	2

Other funds holding NGM

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Rho Capital Partners's NGM Position: Q2 2022 in Review

Rho Capital Partners sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2022, closing a stake of 3,766,666 shares — an estimated $57.4M sold.

Rho Capital Partners first reported a position in NGM in Q2 2019 and held it in 12 quarters. The position peaked at $114M in Q4 2020. 123 funds tracked by Wall St. Rank hold NGM as of Q2 2022.

Rho Capital Partners reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Rho Capital Partners sold 3,766,666 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $57.4M.
Rho Capital Partners first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
Rho Capital Partners's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $114M in Q4 2020.
123 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Rho Capital Partners's 13F filing for Q2 2022, filed 1 Aug 2022.